GPT + Rosalind: What OpenAI’s Life Sciences Model Actually Changes in Drug Development
The life sciences world is bracing for a familiar wave: a breakthrough model, a new acronym, and a promise that “drug discovery will be faster.” But the real questio…
GPT-Rosalind: What OpenAI’s Life Sciences Model Actually Does to Drug Development Read Post »
Fatigue is a common side effect of Lipitor, a medication used to lower cholesterol levels and prevent heart disease. According… https://www.Drugchatter.com/chat/16688/do-you-often-feel-tired-after-taking-lipitor/
DrugChatter: Do you often feel tired after taking lipitor? Read Post »
Yervoy, also known as ipilimumab, is a medication used to treat melanoma. It has been on the market since March 2011 and… https://www.Drugchatter.com/chat/23203/any-news-on-yervoy-s-patent-expiration/
DrugChatter: Any news on yervoy s patent expiration? Read Post »
Biosimilars don’t lose on science. They lose on timing.
Most teams in biosimilars wait until the “patent expiry date” becomes a calendar event. By then, the real work—capacity planning, equipment procurement, process validation, and regulatory readines…
Drug patent protection in Europe: it sounds simple—until you look at the clock.
For years, “how long does a drug patent last?” has been treated like a straightforward question. But in Europe, the answer is less a single date on a calendar and more a mo…
European Drug Patents: Exactly How Long Protection Lasts — and Where It Breaks Down Read Post »
Drug discovery timelines are getting longer—and the cost of waiting is getting unbearable.
That’s the tension at the heart of the latest push to “slash” development timelines with AI. In a world where a single delay can mean millions in additional burn…
Slash drug discovery timelines with GPT-Rosalind Read Post »
The “Patent Expiration Cliff” Is Coming—So Why Are Many Commercial Teams Still Waiting for It to Arrive?
In pharma, the calendar is destiny. But for commercial market access teams, the real inflection point isn’t the day a patent expires—it’s the weeks…
Authorized Generics: The Innovator’s Playbook for Diluting First-Filer Profits
The first-filer advantage in pharma is supposed to be a clean story: win the patent fight, launch early, capture premium pricing, and harvest the exclusivity runway before t…
Authorized Generics: The Innovator’s Playbook for Diluting First-Filer Profits Read Post »
Read the clock right: Mapping regulatory exclusivities for true generic entry timing
Most people think “generic entry” is a single date on a calendar. In reality, it’s a moving target—set by a web of regulatory exclusivities, patent thickets, and timin…
Unlocking the Hidden Clock: How Precise Mapping of Regulatory Exclusivities Can Accelerate Generic Drug Entry
In the complex world of pharmaceutical innovation and market competition, timing is everything. Yet, for many stakeholders—manufacturers, inve…
Get new actionable insights and updates from BiotechBlog
